2026-01-18 - Analysis Report
**English Report**
================

### Company Overview
Regeneron Pharmaceuticals Inc, a company that focuses on developing medications for severe diseases.

### Return Rate Comparison
- **Review Stock**: Cumulative return of REGN = 25.37%
- **Comparison Stock (VOO)**: Cumulative return = 93.36%
- **Divergence**: -66.60, relative divergence = 21.20%

### Analysis of Return Rate Comparison
The comparison of the return rate shows significant divergence between REGN (25.37%) and VOO (93.36%), indicating a significant underperformance of REGN.

### Alpha and Beta Analysis
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | -14.0% | 22.4% | -18.0% | 1.2 | 39.6B |
| 2017-2019  | -3.0% | 28.6% | -21.0% | 1.0 | 39.8B |
| 2018-2020  | 2.0% | 28.6% | -19.0% | 0.7 | 51.2B |
| 2019-2021  | 29.0% | 28.6% | -15.0% | 0.6 | 66.9B |
| 2020-2022  | 55.0% | 14.4% | 56.0% | 0.6 | 76.5B |
| 2021-2023  | 46.0% | 14.4% | 45.0% | 0.6 | 93.1B |
| 2022-2024  | -7.0% | 30.9% | -26.0% | 0.6 | 75.5B |
| 2023-2025  | -4.0% | 45.4% | -66.0% | 0.6 | 81.8B |

### Recent Stock Price Fluctuations
- **Close**: $733.04
- **Last-Market**: $733.04 (-1.17% from previous close)
- **5-DMA**: $751.20
- **20-DMA**: $772.91
- **60-DMA**: $721.13

### Market Risk Indicator (MRI) and Technical Indicators Analysis
- **Market Risk Indicator (MRI)**: 0.80, indicating a medium-risk investment.
- **RSI**: 33.66, suggesting that the stock is oversold.
- **PPO**: -1.10, indicating a sell signal.
- **Expected Return**: -44.70%

### Recent News and Significant Events
- [2026-01-02] Regeneron Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on January 30, 2026 - Quiver Quantitative
- [2026-01-14] Is Regeneron (REGN) Offering Value After Recent Share Price Swings? - Yahoo Finance
- [2026-01-16] Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by PGGM Investments - MarketBeat
- [2026-01-02] REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? - Zacks Investment Research
- [2026-01-12] Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: A Strong Buy with 15.19% Return on Equity and 3.53% Potential Upside - DirectorsTalk Interviews
- [2026-01-06] REGN vs. ILMN: Which Stock Should Value Investors Buy Now? - Nasdaq

### Analyst Opinions
- Analyst Consensus:
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 1.69
  - Opinions: 26
  - Target Price (avg/high/low): $826.04 / $1057.00 / $630.00

### Recent Earnings Analysis
| Date | EPS | Revenue |
|------|-----|---------|
| 2025-10-28 | 14.09 | 3.75 B$ |
| 2025-08-01 | 13.24 | 3.68 B$ |
| 2025-04-29 | 7.58 | 3.03 B$ |
| 2024-10-31 | 12.4 | 3.72 B$ |
| 2025-10-28 | 12.4 | 3.72 B$ |

### Financial Information - Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $3.75B | 86.11% |
| 2025-06-30 | $3.68B | 85.58% |
| 2025-03-31 | $3.03B | 84.67% |
| 2024-12-31 | $3.79B | 85.08% |
| 2024-09-30 | $3.72B | 86.80% |

### Financial Information - Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $30.96B | 4.72% |
| 2025-06-30 | $29.94B | 4.65% |
| 2025-03-31 | $29.39B | 2.75% |
| 2024-12-31 | $29.35B | 3.13% |
| 2024-09-30 | $29.33B | 4.57% |

### Comprehensive Analysis
The comprehensive analysis of REGN reveals a high level of divergence in return rate compared to the comparison stock VOO, oversold condition, and a weak Market Risk Indicator.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.